Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499213 | 0.91 | UTS2R (0.35) | MAPTUTS2RPDK2KDM4EGAA | |
| SCHEMBL498979 | 0.87 | UTS2R (0.33) | MAPTUTS2RPDK2KDM4EGAA | |
| SCHEMBL499588 | 0.86 | IDO1 (0.39) | MAPTUTS2RKDM4EAHCYIDO1 | |
| SCHEMBL4757403 | 0.86 | MAPT (0.42) | MAPTUTS2RKDM4EGAAMAPK1 | |
| SCHEMBL498970 | 0.85 | UTS2R (0.34) | MAPTUTS2RKDM4EGAAAHCY | |
| SCHEMBL4756782 | 0.83 | IDO1 (0.37) | MAPTKDM4EAHCYIDO1 | |
| SCHEMBL499662 | 0.82 | MAPT (0.38) | MAPTUTS2RPDK2KDM4EGAA | |
| SCHEMBL499224 | 0.75 | AOC3 (0.40) | UTS2RPDK2KDM4EIDO1 | |
| SCHEMBL31462515 | 0.74 | AHCY (0.37) | MAPTKDM4EGAAMAPK1AHCY | |
| SCHEMBL31462628 | 0.74 | AHCY (0.37) | MAPTKDM4EGAAMAPK1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | MAPT 935/4885UTS2R 520/4885PDK2 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.